Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies

Open access

Abstract

Neutralizing antibodies to adeno-associated virus (AAV) vectors are highly prevalent in humans 1,2, and block liver transduction 3-5 and vector readministration 6; thus, they represent a major limitation to in vivo gene therapy. Strategies aimed at overcoming anti-AAV antibodies are being studied 7, which often involve immunosuppression and are not efficient in removing pre-existing antibodies. Imlifidase (IdeS) is an endopeptidase able to degrade circulating IgG that is currently being tested in transplant patients 8. Here, we studied if IdeS could eliminate anti-AAV antibodies in the context of gene therapy. We showed efficient cleavage of pooled human IgG (intravenous Ig) in vitro upon endopeptidase treatment. In mice passively immunized with intravenous Ig, IdeS administration decreased anti-AAV antibodies and enabled efficient liver gene transfer. The approach was scaled up to nonhuman primates, a natural host for wild-type AAV. IdeS treatment before AAV vector infusion was safe and resulted in enhanced liver transduction, even in the setting of vector readministration. Finally, IdeS reduced anti-AAV antibody levels from human plasma samples in vitro, including plasma from prospective gene therapy trial participants. These results provide a potential solution to overcome pre-existing antibodies to AAV-based gene therapy.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-020-0911-7

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 27 references

Cited by

See all 336

Metadata

Authors
Leborgne, C., Barbon, E., Alexander, J. M., Hanby, H., Delignat, S., Cohen, D. M., Collaud, F., Muraleetharan, S., Lupo, D., Silverberg, J., Huang, K., van Wittengerghe, L., Marolleau, B., Miranda, A., Fabiano, A., Daventure, V., Beck, H., Anguela, X. M., Ronzitti, G., Armour, S. M., Lacroix-Desmazes, S., & Mingozzi, F.
Affiliations
  • Inserm (FR)
  • Spark Therapeutics (United States) (US)
Corresponding author
Mingozzi, Federico
Venue
Nature Medicine
Published
2020-06-01
Volume
26
Issue
7
Pages
1096-1101
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3032166296
Cited by
336
References
27
Citations by year
2026: 50 · 2025: 53 · 2024: 43 · 2023: 60 · 2022: 64 · 2021: 43 · 2020: 21
FWCI
27.51
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • HAL (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
Keywords
adeno-associated virus vectors, ide, antibody neutralization, liver gene transfer, in vivo gene therapy, non-human primates, human plasma
MeSH terms
Dependovirus, Animals, Antibodies, Anti-Idiotypic, Antibodies, Viral, Capsid, Genetic Vectors, Humans, Immunoglobulin G, Liver, Endopeptidases, Genetic Therapy, Mice, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. https://app.cochat.ai/papers/10.1038/s41591-020-0911-7
The paper
Leborgne, C., Barbon, E., Alexander, J. M., Hanby, H., Delignat, S., Cohen, D. M., Collaud, F., Muraleetharan, S., Lupo, D., Silverberg, J., Huang, K., van Wittengerghe, L., Marolleau, B., Miranda, A., Fabiano, A., Daventure, V., Beck, H., Anguela, X. M., Ronzitti, G., . . . Mingozzi, F. (2020). IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nature Medicine. https://doi.org/10.1038/s41591-020-0911-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.